Cargando…

Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19

Background: There is limited data in the literature about the clinical importance and prognosis of pericardial effusion (PE) in patients discharged after recovering from COVID-19, but large-scale studies have yet to be available. This study investigated the prevalence, risk factors, prognosis, late...

Descripción completa

Detalles Bibliográficos
Autores principales: Saraç, İbrahim, Aydın, Sidar Şiyar, Özmen, Murat, Doru, Halil İbrahim, Tonkaz, Gökhan, Çırçır, Melike Nur, Akpınar, Furkan, Zengin, Onur, Delice, Orhan, Aydınyılmaz, Faruk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531872/
https://www.ncbi.nlm.nih.gov/pubmed/37754797
http://dx.doi.org/10.3390/jcdd10090368
_version_ 1785111822405206016
author Saraç, İbrahim
Aydın, Sidar Şiyar
Özmen, Murat
Doru, Halil İbrahim
Tonkaz, Gökhan
Çırçır, Melike Nur
Akpınar, Furkan
Zengin, Onur
Delice, Orhan
Aydınyılmaz, Faruk
author_facet Saraç, İbrahim
Aydın, Sidar Şiyar
Özmen, Murat
Doru, Halil İbrahim
Tonkaz, Gökhan
Çırçır, Melike Nur
Akpınar, Furkan
Zengin, Onur
Delice, Orhan
Aydınyılmaz, Faruk
author_sort Saraç, İbrahim
collection PubMed
description Background: There is limited data in the literature about the clinical importance and prognosis of pericardial effusion (PE) in patients discharged after recovering from COVID-19, but large-scale studies have yet to be available. This study investigated the prevalence, risk factors, prognosis, late clinical outcomes, and management of PE in COVID-19. Materials and Methods: Between August 2020 and March 2021, 15,689 patients were followed up in our pandemic hospital due to COVID-19. Patients with positive polymerase chain reaction (PCR) test results and PE associated with COVID-19 in computed tomography (CT) were included in the study. The patients were divided into three groups according to PE size (mild, moderate, and large). Transthoracic echocardiography (TTE) records, laboratory data, clinical outcomes, and medical treatments of patients discharged from the hospital were retrospectively reviewed. Results: According to the PE size (mild, moderate, large) of 256 patients with PE at admission or discharge, the mean age was 62.17 ± 16.34, 69.12 ± 12.52, and 72.44 ± 15.26, respectively. The mean follow-up period of the patients was 25.2 ± 5.12 months. Of the patients in the study population, 53.5% were in the mild group, 30.4% in the moderate group, and 16.1% in the large group. PE became chronic in a total of 178 (69.6%) patients at the end of the mean three months, and chronicity increased as PE size increased. Despite the different anti-inflammatory treatments for PE in the acute phase, similar chronicity was observed. In addition, as the PE size increased, the patients’ frequency of hospitalization, complications, and mortality rates showed statistical significance between the groups. Conclusions: The clinical prognosis of patients presenting with PE was quite poor; as PE in size increased, cardiac and noncardiac events and mortality rates were significantly higher. Patients with large PE associated with COVID-19 at discharge should be monitored at close intervals due to the chronicity of PE and the increased risk of tamponade.
format Online
Article
Text
id pubmed-10531872
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105318722023-09-28 Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19 Saraç, İbrahim Aydın, Sidar Şiyar Özmen, Murat Doru, Halil İbrahim Tonkaz, Gökhan Çırçır, Melike Nur Akpınar, Furkan Zengin, Onur Delice, Orhan Aydınyılmaz, Faruk J Cardiovasc Dev Dis Article Background: There is limited data in the literature about the clinical importance and prognosis of pericardial effusion (PE) in patients discharged after recovering from COVID-19, but large-scale studies have yet to be available. This study investigated the prevalence, risk factors, prognosis, late clinical outcomes, and management of PE in COVID-19. Materials and Methods: Between August 2020 and March 2021, 15,689 patients were followed up in our pandemic hospital due to COVID-19. Patients with positive polymerase chain reaction (PCR) test results and PE associated with COVID-19 in computed tomography (CT) were included in the study. The patients were divided into three groups according to PE size (mild, moderate, and large). Transthoracic echocardiography (TTE) records, laboratory data, clinical outcomes, and medical treatments of patients discharged from the hospital were retrospectively reviewed. Results: According to the PE size (mild, moderate, large) of 256 patients with PE at admission or discharge, the mean age was 62.17 ± 16.34, 69.12 ± 12.52, and 72.44 ± 15.26, respectively. The mean follow-up period of the patients was 25.2 ± 5.12 months. Of the patients in the study population, 53.5% were in the mild group, 30.4% in the moderate group, and 16.1% in the large group. PE became chronic in a total of 178 (69.6%) patients at the end of the mean three months, and chronicity increased as PE size increased. Despite the different anti-inflammatory treatments for PE in the acute phase, similar chronicity was observed. In addition, as the PE size increased, the patients’ frequency of hospitalization, complications, and mortality rates showed statistical significance between the groups. Conclusions: The clinical prognosis of patients presenting with PE was quite poor; as PE in size increased, cardiac and noncardiac events and mortality rates were significantly higher. Patients with large PE associated with COVID-19 at discharge should be monitored at close intervals due to the chronicity of PE and the increased risk of tamponade. MDPI 2023-08-27 /pmc/articles/PMC10531872/ /pubmed/37754797 http://dx.doi.org/10.3390/jcdd10090368 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Saraç, İbrahim
Aydın, Sidar Şiyar
Özmen, Murat
Doru, Halil İbrahim
Tonkaz, Gökhan
Çırçır, Melike Nur
Akpınar, Furkan
Zengin, Onur
Delice, Orhan
Aydınyılmaz, Faruk
Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19
title Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19
title_full Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19
title_fullStr Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19
title_full_unstemmed Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19
title_short Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19
title_sort prevalence, risk factors, prognosis, and management of pericardial effusion in covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531872/
https://www.ncbi.nlm.nih.gov/pubmed/37754797
http://dx.doi.org/10.3390/jcdd10090368
work_keys_str_mv AT saracibrahim prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19
AT aydınsidarsiyar prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19
AT ozmenmurat prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19
AT doruhalilibrahim prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19
AT tonkazgokhan prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19
AT cırcırmelikenur prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19
AT akpınarfurkan prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19
AT zenginonur prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19
AT deliceorhan prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19
AT aydınyılmazfaruk prevalenceriskfactorsprognosisandmanagementofpericardialeffusionincovid19